Program
Capecitabine
Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 430 open or running | phase 4since Jul 12, 2004 | May 2, 2000 | none ahead |
| Sanofi | 90 open or running | phase 3since Apr 20, 2004 | Apr 20, 2004 | none ahead |
| R-Pharm | 60 open or running | phase 3since Mar 26, 2004 | Nov 12, 2002 | none ahead |
| Novartis | 41 open or running | phase 3since Jul 26, 2007 | Jul 26, 2007 | Apr 14, 2027phase 2 · NCT06247995 |
| Qilu Pharmaceutical | 21 open or running | phase 2since Jun 1, 2024 | Feb 10, 2018 | none ahead |
| academy-military-medical-science-china | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| bio-cancer-treatment-international-limited | 10 open or running | phase 2since Mar 14, 2014 | Mar 14, 2014 | none ahead |
| ebg-medaustron-gmbh | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| iOMEDICO | 10 open or running | phase 4since Aug 28, 2014 | Aug 28, 2014 | none ahead |
| NovoCure | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| pharmatech-oncology | 10 open or running | phase 2since Nov 9, 2001 | Nov 9, 2001 | none ahead |
| Pierre Fabre | 10 open or running | phase 2since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| prologue-research-international | 10 open or running | phase 3since Jun 5, 2003 | Jun 5, 2003 | none ahead |
Also a collaborator on its studies: Exelixis, clovis-oncology-inc, Johnson & Johnson, parexel, baili-bio-chengdu-pharmaceutical-co-ltd, Zai Lab, chengdu-biostar-pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and yakult-honsha-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jul 12, 2004.
- Nov 17, 2014Phase 2 study in NeoplasmsNovartis · NCT02294786 · 62 enrolled · Czechia, Israel, Poland and more
- Sep 24, 20152 phase 3 studies in Stomach NeoplasmsHoffmann-La Roche · NCT02560974, NCT02563054
- Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsHoffmann-La Roche · NCT02565641 · 63 enrolled · Korea, Republic of
- Oct 1, 20152 phase 4 studies in Colorectal NeoplasmsHoffmann-La Roche · NCT02567331, NCT02581423
- Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularHoffmann-La Roche · NCT02576964 · 16 enrolled · China, Taiwan, Thailand
- Nov 16, 2015Phase 2 study in Nasopharyngeal NeoplasmsHoffmann-La Roche · NCT02608073 · 45 enrolled · Hong Kong, Indonesia, Malaysia and more
- Feb 25, 2016Phase 2 study in Rectal NeoplasmsHoffmann-La Roche · NCT02694718 · 60 enrolled · Switzerland
- Jul 25, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02846428 · 182 enrolled · France
- Oct 3, 2016Pierre Fabre's first study: phase 2 study in Breast NeoplasmsNew to Pierre FabrePierre Fabre · NCT03887130 · 152 enrolled
- Feb 10, 2018Qilu Pharmaceutical's first study: phase 1 study in Colonic NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT03435666 · 45 enrolled
- Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
- May 10, 2021ebg-medaustron-gmbh's first study: no phase study in Pancreatic NeoplasmsNew to ebg-medaustron-gmbhebg-medaustron-gmbh · NCT04894643 · 10 planned · Austria
- Jan 17, 2024Phase 2 study in Breast NeoplasmsNovartis · NCT06247995 · 20 enrolled · United States, Australia, Canada and more
- Jun 1, 2024Phase 2 study in Advanced Solid TumorQilu Pharmaceutical · NCT06446388 · 360 planned · China
Ahead
- Dec 31, 2026Primary completion: no phase study in Pancreatic Neoplasmsebg-medaustron-gmbh · NCT04894643
- Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT06247995
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Fluorouracilrule | Sanofi | phase 4 | 82 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06446388Advanced Solid Tumor · China | 2 | Not yet recruiting | Qilu Pharmaceutical | Jun 30, 2026 | 360 |
| NCT06247995Breast Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Novartis | Apr 14, 2027 | 20 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | ebg-medaustron-gmbh | Dec 31, 2026 | 10 |
| NCT04281576Stomach Neoplasms · Hong Kong | – | Completed | NovoCure | Jun 7, 2024 | 28 |
| NCT03435666Colonic Neoplasms | 1 | UNKNOWN | Qilu Pharmaceutical | Oct 2018 | 45 |
| NCT03887130Breast Neoplasms | 2 | Completed | Pierre Fabre | Apr 18, 2013 | 152 |
| NCT02846428Breast Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Dec 2011 | 182 |
| NCT02694718Rectal Neoplasms · Switzerland | 2 | Completed | Hoffmann-La Roche | Aug 2006 | 60 |
| NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more | 2 | Completed | Hoffmann-La Roche | Nov 2009 | 45 |
| NCT02581423Colorectal Neoplasms · Bulgaria | 4 | Completed | Hoffmann-La Roche | Mar 2007 | 63 |
| NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand | 2 | Completed | Hoffmann-La Roche | Nov 2008 | 16 |
| NCT02567331Colorectal Neoplasms · Bulgaria | 4 | Completed | Hoffmann-La Roche | Apr 2006 | 28 |
| NCT02565641Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Hoffmann-La Roche | Sep 2006 | 63 |
| NCT02563054Stomach Neoplasms · Argentina, Belize, Brazil and more | 3 | Completed | Hoffmann-La Roche | Aug 2010 | 316 |
| NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Hoffmann-La Roche | Nov 2012 | 1,035 |
| NCT02294786Neoplasms · Czechia, Israel, Poland and more | 2 | Terminated | Novartis | Oct 19, 2017 | 62 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02248571Breast Neoplasms · Germany | 4 | Completed | iOMEDICO | Aug 31, 2017 | 85 |
| NCT02089633Carcinoma, Hepatocellular · Hong Kong | 2 | Completed | bio-cancer-treatment-international-limited | Sep 2016 | 17 |
| NCT02085005Colorectal Cancer Metastatic | 2 | Withdrawn | Sanofi | Aug 2016 | 0 |
| NCT02013830Liver Neoplasms · Australia, Hong Kong, Singapore and more | 2 | Completed | Hoffmann-La Roche | Mar 2008 | 45 |
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Sanofi | Mar 2015 | 4 |
| NCT01783444Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Novartis | Jul 2, 2018 | 309 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Hoffmann-La Roche | Aug 21, 2015 | 34 |
| NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 296 |
| NCT01290718Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | Dec 2012 | 4 |
| NCT01245582Carcinoma, Hepatocellular | 3 | Withdrawn | Sanofi | Feb 2014 | 0 |
| NCT01227707Colorectal Neoplasms · Italy | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 43 |
| NCT01135498Colorectal Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Apr 2010 | 90 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jun 2014 | 36 |
| NCT01118377Brainstem Glioma · United States | 2 | Completed | Hoffmann-La Roche | Jan 2013 | 45 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Hoffmann-La Roche | Jan 2012 | 75 |
| NCT01077726Breast Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Dec 2010 | 3 |
| NCT00977379Breast Neoplasms · France | 2 | Terminated | Hoffmann-La Roche | Feb 2011 | 24 |
| NCT00929240Breast Neoplasms · Brazil, China, Egypt and more | 3 | Completed | Hoffmann-La Roche | Jun 2014 | 287 |
| NCT00925769Pancreatic Neoplasms · Austria | 1 | Completed | Hoffmann-La Roche | Dec 2013 | 32 |
| NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more | 2 | Completed | Hoffmann-La Roche | Feb 18, 2013 | 33 |
| NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more | 2 | Completed | Hoffmann-La Roche | Dec 2015 | 88 |
| NCT00796718Colorectal Neoplasms · Slovakia | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 62 |
| NCT00717951Advanced Breast Cancer | 2 | UNKNOWN | academy-military-medical-science-china | Dec 2009 | 120 |
| NCT00634088Breast Neoplasms · United States, Australia, Italy | 1 | Terminated | R-Pharm | Jun 2010 | 13 |
| NCT00623805Colorectal Neoplasms · Turkey | 3 | Completed | Hoffmann-La Roche | May 2012 | 123 |
| NCT00577031Colorectal Neoplasms · Italy | 4 | Completed | Hoffmann-La Roche | Aug 2011 | 205 |
| NCT00576901Breast Neoplasms · Spain | 2 | Terminated | Hoffmann-La Roche | Jun 2009 | 23 |
| NCT00568022Breast Neoplasms · Japan | 1 | Completed | R-Pharm | Jan 2010 | 9 |
| NCT00532948Glioma · United States | 1 | Completed | Hoffmann-La Roche | Oct 2010 | 24 |
| NCT00508274Breast Neoplasms · China, Hong Kong | 3 | Terminated | Novartis | Dec 2, 2015 | 52 |
| NCT00502671Colorectal Neoplasms · Russian Federation | 4 | Completed | Hoffmann-La Roche | Mar 2012 | 228 |
| NCT00448136Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Nov 2011 | 83 |
| NCT00421824Rectal Neoplasms · Spain | 2 | Completed | Sanofi | Nov 2010 | 108 |
| NCT00411229Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Nov 2012 | 1,035 |
| NCT00382720Stomach Neoplasms · United States, Belgium, France and more | 2 | Completed | Sanofi | Apr 2010 | 275 |
| NCT00345761Colorectal Neoplasms · Japan | 2 | Completed | Hoffmann-La Roche | Oct 2008 | 64 |
| NCT00263029Rectal Neoplasms | 2 | Completed | Sanofi | Mar 2007 | 18 |
| NCT00207129Neoplasms · United States | 1 | Completed | R-Pharm | Dec 2005 | 25 |
| NCT00174616Rectal Neoplasms · Belgium, France, Germany and more | 2 | Completed | Sanofi | Nov 2007 | 87 |
| NCT00121836Breast Neoplasms · United States | 4 | Completed | Hoffmann-La Roche | Dec 2008 | 109 |
| NCT00118755Colorectal Neoplasms | 2 | Completed | Hoffmann-La Roche | Apr 2009 | 435 |
| NCT00112918Colorectal Neoplasms · United States | 3 | Completed | Hoffmann-La Roche | Jun 2010 | 3,451 |
| NCT00087620Breast Neoplasms · United States | 4 | Terminated | Hoffmann-La Roche | Oct 2004 |
How it is read
Names in the registry
- “Capecitabine”, 62 entries
- “capecitabine”, 16 entries
- “capecitabine [Xeloda]”, 12 entries
- “Utidelone in combination with capecitabine”, 3 entries
- “Capecitabine [Xeloda]”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 44 studies
- Colorectal Neoplasms, 21 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 6 studies
- Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.